GeneDx Holdings Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WGS research report →
Range $63 – $90
Price Chart
About the company
GeneDx Holdings Corp. , a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
- CEO
- Katherine A. Stueland
- IPO
- 2020
- Employees
- 1,300
- HQ
- Stamford, CT, US
Get TickerSpark's AI analysis on WGS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.36B
- P/E
- -12.03
- Fwd P/E
- 109.10
- PEG
- -0.01
- P/S
- 2.96
- P/B
- 5.55
- EV/EBITDA
- -18.59
- Div Yield
- 0.00%
- Gross Margin
- 67.59%
- Op Margin
- -14.71%
- Net Margin
- -24.10%
- ROE
- -42.26%
- ROIC
- -14.71%
Latest fiscal year · YoY change
- Revenue
- $427.54M+40.0%
- Gross Profit
- $298.17M+53.4%
- Op Income
- $-11,802,000
- Net Income
- $-21,021,000+59.8%
- EPS
- $-0.73+62.4%
- OCF Growth
- +216.8%
- FCF Growth
- +142.0%
- 52W High
- $170.87
- 52W Low
- $32.21
- 50D MA
- $70.18
- 200D MA
- $68.82
- Beta
- 1.99
- RSI (14)
- 34
- Avg Volume
- 869.34K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
GeneDx delivered another quarter of stronger margins and profitability, but near-term volume growth was intentionally slowed by tougher upfront documentation requirements as the company pushes for better collections.· November 9, 2026
- Q3 revenue was $123.1 million, adjusted gross margin was 72%, and adjusted net income was $8.6 million.
- Average reimbursement rose about 5% sequentially to $3,436, helped by improved genome collections and mix shifts.
- Management raised full-year adjusted gross margin guidance to about 71% and adjusted net income guidance to at least $12 million, while reaffirming revenue guidance of $475 million-$490 million.
- Outpatient genome collection rate improved to 36% from 32% last quarter, but outpatient genome mix fell to 26% from 32% as the company prioritized payer documentation upfront.
- Management said most RCM benefits should show up in 2027 and beyond, while PAMA is expected to create a mid-single-digit 2027 revenue headwind.
Third quarter 2026 total revenue was $123.1 million, including $110.4 million of exome genome revenue, which was up $10 million sequentially. Adjusted gross margin expanded to 72% from 69% in Q1 and 70% in Q2, and adjusted net income improved to $8.6 million from an $8.2 million loss in Q1 and near break-even in Q2. The blended average reimbursement rate was $3,436 in Q3, up 5% from $3,258 in Q2. The company reported over 32,100 exome and genome tests. For full year 2026, GeneDx raised adjusted gross margin guidance to approximately 71% and adjusted net income guidance to at least $12 million, reaffirmed revenue guidance of $475 million-$490 million and said results should come at the low end of that range, and lowered exome and genome volume growth guidance to at least 28% while exome and genome revenue growth is now expected to be at least 17%. For Q4, it guided to ARR of approximately $3,500 a test, adjusted gross margin of at least 71%, adjusted net income of approximately $12 million, total revenue of at least $135 million, and exome and genome revenue of $121 million on result volume of 34,500 tests.
Katherine Stueland framed the quarter as proof that GeneDx is balancing profitable growth with market expansion. She emphasized three priorities: improving unit economics, growing utilization, and delivering leading products at scale, while saying the company is building a more sustainable model that supports reinvestment. Her tone was confident and mission-driven, highlighting strong demand, new product features, long-read sequencing, and the broader value of GeneDx Infinity beyond core diagnostics.
Kevin Feeley focused on sequential improvement in revenue quality and margins. He highlighted $123.1 million of Q3 revenue, 72% adjusted gross margin, $8.6 million of adjusted net income, and a 5% sequential increase in average reimbursement to $3,436. He also pointed to outpatient genome collection rate improvement to 36% from 32%, genome cost per test down 43% year over year, and said the company expects to take at least a few hundred more dollars out of genome COGS over the next several quarters. On capital and outlook, he raised full-year margin and profit guidance, reaffirmed revenue guidance, and said about 45% of revenue is subject to PAMA, implying a mid-single-digit 2027 revenue headwind that revenue cycle improvements can offset or more than offset.
Analysts focused on the lower volume outlook, asking whether the documentation changes are suppressing volume or merely delaying it. Management said most of the effect is timing, not permanent loss, with accession growth of 28% versus reported volume growth of 25% largely reflecting a few-day lag from added paperwork; they said substantially all of that demand should ultimately convert. Questions also centered on GenPeds, prenatal and NICU opportunities, trios, and long-read sequencing. Management said GenPeds is already paying for itself and should be the largest single segment among its channels, trios were relatively flat, NICU and prenatal are growing well, and long-read is being launched through an early access program with KOL input on use criteria.
The call showed improving financial execution, with gross margin, reimbursement, and net income all moving in the right direction. Management also described strong demand across customer segments, early signs that new commercial bets like GenPeds are working, and growing value from data and new technologies like long-read sequencing. The company said RCM and coverage improvements should create a better 2027 setup even after PAMA.
Near-term volume is softer because GeneDx is deliberately asking for more payer documentation upfront, which management said will slow reported volume and likely keep 2026 volume below earlier expectations. Genome mix fell sharply quarter over quarter, and management said some payer changes such as Medi-Cal still remain operationally difficult and may not fully benefit until 2027. The company also warned that about 45% of revenue is exposed to PAMA, creating a mid-single-digit 2027 headwind.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.9%
- Shares Outstanding
- 29.97M
- Float Shares
- 29.04M
of shares held by institutions
242 13F filers
Buy/sell ratio 0.32. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Corvex Management LP | 4.78M | ▲ 1.56M |
| Casdin Capital, LLC | 3.71M | ▲ 700.00K |
| Ark Investment Management LLC | 1.91M | ▲ 302.93K |
| Blackrock, Inc. | 1.69M | ▼ 12.31K |
| Goldman Sachs Group Inc | 1.67M | ▲ 334.46K |
| William Blair Investment Management, LLC | 1.56M | ▲ 159.59K |
| Vanguard Group Inc | 1.19M | ▲ 18.65K |
| Morgan Stanley | 1.01M | ▲ 26.64K |
| Vanguard Capital Management LLC | 948.76K | ▲ 69.76K |
| Oracle Investment Management Inc | 884.65K | ▼ 5.30K |
| Citadel Advisors LLC | 865.46K | ▲ 218.06K |
| First Light Asset Management, LLC | 783.92K | ▲ 541.00K |
Held by 259 ETFs
Biggest fund positions in WGS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Stueland Katherine | other | 18,750 |
| Sep 16, 26 | Stueland Katherine | sell | 1,648 |
| Sep 16, 26 | Stueland Katherine | sell | 148 |
| Sep 16, 26 | Stueland Katherine | sell | 1,525 |
| Sep 16, 26 | Stueland Katherine | sell | 4,141 |
| Sep 16, 26 | Stueland Katherine | sell | 3,039 |
| Sep 16, 26 | Stueland Katherine | other | 18,750 |
| Sep 16, 26 | Feeley Kevin | other | 7,197 |
| Sep 16, 26 | Feeley Kevin | sell | 586 |
| Sep 16, 26 | Feeley Kevin | sell | 52 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WGS coverage
Recent articles, reports, and earnings notes.
No research on WGS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WGS report →GeneDx Announces Leadership Transition
businesswire.com · Nov 18
GeneDx Holdings Corp. $WGS Stock: Aberdeen Group plc Lowers Position
defenseworld.net · Nov 17
GeneDx to Participate in Upcoming Investor Conferences
businesswire.com · Nov 11
Why GeneDx Holdings Stock Just Dropped 16.6%
fool.com · Nov 10
4 Post-Earnings Losers Drawing Unusual Options Volume
schaeffersresearch.com · Nov 10
GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients
businesswire.com · Nov 10
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability
seekingalpha.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.